S. Karger AG

SHERPA: Unknown

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Abou-Alfa
    Abou-Alfa
  4. Hellmann
    Hellmann
  5. Matasar
    Matasar
  6. O'Reilly
    O'Reilly
  7. Janjigian
    Janjigian
  8. Salles
    Salles
  9. Usmani
    Usmani
  10. Giralt
    Giralt

Groups

  1. Department of Medicine (198)
  2. Solid Tumor Oncology Division (132)
  3. Hematologic Malignancies, Division of (71)
  4. Center for Hematologic Malignancies (60)
  5. Gastrointestinal Oncology Service (46)
  6. Thoracic Oncology (44)
  7. Genitourinary Oncology Service (27)
  8. Lymphoma (21)
  9. Adult Leukemia (18)
  10. GSK Faculty (18)
Search Within
  1. "Oncology Research and Treatment"
Formats
  1. Meeting Abstract (223)
  2. Journal Article (2)
Groups
  1. Department of Medicine (198)
  2. Solid Tumor Oncology Division (132)
  3. Hematologic Malignancies, Division of (71)
  4. Center for Hematologic Malignancies (60)
  5. Gastrointestinal Oncology Service (46)
  6. Thoracic Oncology (44)

More Groups

People
  1. Alexander Drilon (23)
  2. Robert Motzer (20)
  3. Ghassan Abou-Alfa (18)
  4. Yelena Janjigian (11)
  5. Matthew Hellmann (9)
  6. Eileen O'Reilly (8)

More People

Years
  1. 2024 (18)
  2. 2023 (34)
  3. 2022 (39)
  4. 2021 (24)
  5. 2020 (36)
  6. 2019 (16)

More Years

Publications
  1. Oncology Research and Treatment (225)

Results (225)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nivolumab monotherapy in metastatic urothelial cancer (mUC): Efficacy (by PD-L1 expression) and safety results from the CheckMate 032 study
    Meeting Abstract

    Jaeger, D.; Sharma, P.; Bono, P.; Kim, J.; Spiliopoulou, P.; Calvo, E.; Pillai, R. N.; Ott, P. A.; de Braud, F.; Morse, M.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study
    Meeting Abstract

    Grünwald, V.; Motzer, R. J.; Sharma, P.; Escudier, B.; McDermott, D. F.; George, S.; Srinivas, S.; Tykodi, S. S.; Sosman, J. A.; Plimack, E. R.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • Improvements in quality of life and overall survival in patients with advanced renal cell carcinoma treated with nivolumab vs everolimus in the phase Ill CheckMate 025 study
    Meeting Abstract

    Grünwald, V.; Cella, D.; Nathan, P.; Doan, J.; Dastahi, H.; Taylor, F.; Bennett, B.; DeRosa, M.; Berry, S.; Broglio, K.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • Synergistic inhibition of chromatin modifiers reverses a leukemogenic gene expression program in NPM1 mutant leukemia
    Meeting Abstract

    Kühn, M. W. M.; Song, E.; Feng, Z.; Sinha, A.; Chen, C. W.; Deshpande, A. J.; Cusan, M.; Farnoud, N. R.; Koche, R. P.; Bradner, J. E.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • CheckMate 017 and 057 studies of nivolumab vs docetaxel in patients with advanced NSCLC: 2-year-update and exploratory cytokine profile analyses
    Meeting Abstract

    Eberhardt, W. E. E.; Borghaei, H.; Brahmer, J. R.; Horn, L.; Ready, N.; Steins, M.; Felip, E.; Paz-Ares, L. G.; Arrieta, O.; Barlesi, F.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • Introducing hyperthermic intraperitoneal chemotherapy into gynecological oncology practice - Feasibility and safety considerations: Single-center experience
    Journal Article

    Abramian, A.; Zivanovic, O.; Kuhn, W.; Weber, S.; Schaefer, N.; Keyver-Paik, M. D.; Kiefer, N.
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • Activation of the cytosolic RNA receptor RIG-I in tumor and immune cells triggers efficient anti-tumor immunity and synergizes with checkpoint blockade
    Meeting Abstract

    Heidegger, S.; Wintges, A.; Kreppel, D.; Bscheider, M.; Bek, S.; Fischer, J.; Schmickl, M.; Ruland, J.; van den Brink, M.; Peschel, C.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • A randomized phase 1b/2 study evaluating the safety and efficacy of doxorubicin (Dox) with or without olaratumab (IMC-3G3), a human anti-platelet-derived growth factor a (pdgfra) monoclonal antibody, in advanced soft tissue sarcoma (sts)
    Meeting Abstract

    Tap, W.; Jones, R. L.; Chmelowski, B.; Elias, A. A.; Adkins, D.; Van Tine, B. A.; Agulnik, M.; Cooney, M.; Livingston, M. B.; Pennock, G.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients with advanced melanoma (MEL) (CheckMate 067)
    Meeting Abstract

    Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J. J.; Cowey, C. L.; Lao, C. D.; Wagstaff, J.; Hogg, D.; Hill, A.; Carlino, M. S.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • Efficacy of rociletinib (CO-1686) in centrally confirmed T790M-positive and T790M-negative non-small cell lung cancer (NSCLC) patients (Pts)
    Meeting Abstract

    Sequist, L. V.; Goldman, J. W.; Wakelee, H.; Camidge, D. R.; Gadgeel, S.; Yu, H. A.; Varga, A.; Solomon, B.; Oxnard, G. R.; Ou, S. H. I.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save